30 July 2026 · news · trials · weight-loss · metabolic · cardiovascular · research · eli-lilly · triumph-program
Retatrutide Achieves 28.3% Weight Loss in Landmark Phase 3 TRIUMPH-1 Trial
The pivotal TRIUMPH-1 Phase 3 trial confirms retatrutide delivered up to 28.3% average weight loss at 80 weeks, with significant cardiometabolic benefits — here's what the data means.
Read more →